Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia. In past decades, intensive studies on the biology and treatment of this disease have resulted in a remarkably thorough understanding of its pathogenesis and improvement of treatment outcomes. In particular, the introduction of all-trans retinoic acid to conventional chemotherapy improved dramatically the remission and survival rates of APL patients and consequently became the major treatment modality for it. In the last decade, the groundbreaking development of arsenic further improved the survival rate of APL patients. As the most active agent in APL, arsenic directly degrades the PML-RARα fusion transcript, leading to the differentiation and apoptosis of leukemia cells and the potential eradication of APL leukemia-initiating cells (LICs), thus making the disease a potentially curable type of leukemia. More notably, the recent development of oral arsenic compounds may further enhance not only clinical outcomes but also the convenience of patients, which may dramatically change the APL clinical scenario in the near future.
Corresponding Author(s):
HU Jiong,Email:hujiong@medmail.com.cn
引用本文:
. Arsenic in the treatment of newly diagnosed acute promyelocytic leukemia: current status and future research direction[J]. Frontiers of Medicine, 2011, 5(1): 45-52.
Jiong HU. Arsenic in the treatment of newly diagnosed acute promyelocytic leukemia: current status and future research direction. Front Med, 2011, 5(1): 45-52.
Rowley J D, Golomb H M, Dougherty C. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet , 1977, 1(8010): 549–550 doi: 10.1016/S0140-6736(77)91415-5 pmid:65649
2
Rousselot P, Hardas B, Patel A, Guidez F, G?ken J, Castaigne S, Dejean A, de Thé H, Degos L, Farzaneh F, .The PML-RAR alpha gene product of the t(15;17) translocation inhibits retinoic acid-induced granulocytic differentiation and mediated transactivation in human myeloid cells. Oncogene , 1994, 9(2): 545–551 pmid:8290265
3
Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood , 2008, 111(5):2505–2515
4
Huang M E, Ye Y C, Chen S R, Chai J R, Lu J X, Zhoa L, Gu L J, Wang Z Y. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood , 1988, 72(2): 567–572 pmid:3165295
5
Rodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood , 1990, 75(11): 2112–2117 pmid:2189506
6
Sanz M A, Martín G, Rayón C, Esteve J, González M, Díaz-Mediavilla J, Bolufer P, Barragán E, Terol M J, González J D, Colomer D, Chillón C, Rivas C, Gómez T, Ribera J M, Bornstein R, Román J, Calasanz M J, Arias J, Alvarez C, Ramos F, Debén G. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood , 1999, 94(9): 3015–3021 pmid:10556184
7
Kelaidi C, Chevret S, De Botton S, Raffoux E, Guerci A, Thomas X, Pigneux A, Lamy T, Rigal-Huguet F, Meyer-Monard S, Chevallier P, Maloisel F, Deconinck E, Ferrant A, Fegueux N, Ifrah N, Sanz M, Dombret H, Fenaux P, Adès L. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. J Clin Oncol , 2009, 27(16): 2668–2676 doi: 10.1200/JCO.2008.18.4119 pmid:19414681
8
Tallman M S, Altman J K. How I treat acute promyelocytic leukemia. Blood , 2009, 114(25): 5126–5135 doi: 10.1182/blood-2009-07-216457 pmid:19797519
9
Shen Z X, Chen G Q, Ni J H, Li X S, Xiong S M, Qiu Q Y, Zhu J, Tang W, Sun G L, Yang K Q, Chen Y, Zhou L, Fang Z W, Wang Y T, Ma J, Zhang P, Zhang T D, Chen S J, Chen Z, Wang Z Y. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood , 1997, 89(9): 3354–3360 pmid:9129042
10
Chen G Q, Zhu J, Shi X G, Ni J H, Zhong H J, Si G Y, Jin X L, Tang W, Li X S, Xong S M, Shen Z X, Sun G L, Ma J, Zhang P, Zhang T D, Gazin C, Naoe T, Chen S J, Wang Z Y, Chen Z. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood , 1996, 88(3): 1052–1061 pmid:8704214
11
Niu C, Yan H, Yu T, Sun H P, Liu J X, Li X S, Wu W, Zhang F Q, Chen Y, Zhou L, Li J M, Zeng X Y, Yang R R, Yuan M M, Ren M Y, Gu F Y, Cao Q, Gu B W, Su X Y, Chen G Q, Xiong S M, Zhang T D, Waxman S, Wang Z Y, Chen Z, Hu J, Shen Z X, Chen S J. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood , 1999, 94(10): 3315–3324 pmid:10552940
12
Soignet S L, Frankel S R, Douer D, Tallman M S, Kantarjian H, Calleja E, Stone R M, Kalaycio M, Scheinberg D A, Steinherz P, Sievers E L, Coutré S, Dahlberg S, Ellison R, Warrell R P Jr. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol , 2001, 19(18): 3852–3860 pmid:11559723
13
Mathews V, George B, Lakshmi K M, Viswabandya A, Bajel A, Balasubramanian P, Shaji R V, Srivastava V M, Srivastava A, Chandy M. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood , 2006, 107(7): 2627–2632 doi: 10.1182/blood-2005-08-3532 pmid:16352810
14
Mathews V, George B, Chendamarai E, Lakshmi K M, Desire S, Balasubramanian P, Viswabandya A, Thirugnanam R, Abraham A, Shaji R V, Srivastava A, Chandy M. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol , 2010, 28(24): 3866–3871 doi: 10.1200/JCO.2010.28.5031 pmid:20644086
15
Ghavamzadeh A, Alimoghaddam K, Ghaffari S H, Rostami S, Jahani M, Hosseini R, Mossavi A, Baybordi E, Khodabadeh A, Iravani M, Bahar B, Mortazavi Y, Totonchi M, Aghdami N. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol , 2006, 17(1): 131–134 doi: 10.1093/annonc/mdj019 pmid:16227315
16
Zhang P, Wang S, Hu L, Qiu F, Yang H, Xiao Y, Li X, Han X, Zhou J, Liu P. Seven years' summary report on the treatment of acute promyelocytic leukemia with arsenic trioxide-an analysis of 242 cases. Chin J Hematol , 2000, 21(2): 67–70
17
Zhou G B, Zhang J, Wang Z Y, Chen S J, Chen Z. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Philos Trans R Soc Lond B Biol Sci , 2007, 362(1482): 959–971 17317642 doi: 10.1098/rstb.2007.2026
18
Lallemand-Breitenbach V, Guillemin M C, Janin A, Daniel M T, Degos L, Kogan S C, Bishop J M, de Thé H. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med , 1999, 189(7): 1043–1052 doi: 10.1084/jem.189.7.1043 pmid:10190895
19
Jing Y, Wang L, Xia L, Chen G Q, Chen Z, Miller W H, Waxman S. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood , 2001, 97(1): 264–269 doi: 10.1182/blood.V97.1.264 pmid:11133770
20
Raffoux E, Rousselot P, Poupon J, Daniel M T, Cassinat B, Delarue R, Taksin A L, Réa D, Buzyn A, Tibi A, Lebbé G, Cimerman P, Chomienne C, Fermand J P, de Thé H, Degos L, Hermine O, Dombret H. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol , 2003, 21(12): 2326–2334 doi: 10.1200/JCO.2003.01.149 pmid:12805334
21
Shen Z X, Shi Z Z, Fang J, Gu B W, Li J M, Zhu Y M, Shi J Y, Zheng P Z, Yan H, Liu Y F, Chen Y, Shen Y, Wu W, Tang W, Waxman S, De Thé H, Wang Z Y, Chen S J, Chen Z. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA , 2004, 101(15): 5328–5335 doi: 10.1073/pnas.0400053101 pmid:15044693
22
Hu J, Liu Y F, Wu C F, Xu F, Shen Z X, Zhu Y M, Li J M, Tang W, Zhao W L, Wu W, Sun H P, Chen Q S, Chen B, Zhou G B, Zelent A, Waxman S, Wang Z Y, Chen S J, Chen Z. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA , 2009, 106(9): 3342–3347 doi: 10.1073/pnas.0813280106 pmid:19225113
23
Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D, Kantarjian H. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood , 2006, 107(9): 3469–3473 doi: 10.1182/blood-2005-10-4006 pmid:16373661
24
Ravandi F, Estey E, Jones D, Faderl S, O’Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W, Ferrajoli A, Verstovsek S, Garcia-Manero G, Cortes J, Kantarjian H. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol , 2009, 27(4): 504–510 doi: 10.1200/JCO.2008.18.6130 pmid:19075265
25
Powell B L, Moser B, Stock W, Gallagher R E, Willman C L, Stone R M, Rowe J M, Coutre S, Feusner J H, Gregory J, Couban S, Appelbaum F R, Tallman M S, Larson R A. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood , 2010, 116(19): 3751–3757 doi: 10.1182/blood-2010-02-269621 pmid:20705755
26
Sanz M A, Grimwade D, Tallman M S, Lowenberg B, Fenaux P, Estey E H, Naoe T, Lengfelder E, Büchner T, D?hner H, Burnett A K, Lo-Coco F. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood , 2009, 113(9): 1875–1891 doi: 10.1182/blood-2008-04-150250 pmid:18812465
27
Zhu J, Lallemand-Breitenbach V, de Thé H. Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission. Oncogene , 2001, 20(49): 7257–7265 doi: 10.1038/sj.onc.1204852 pmid:11704854
28
Zhu J, Zhou J, Peres L, Riaucoux F, Honoré N, Kogan S, de Thé H. A sumoylation site in PML/RARA is essential for leukemic transformation. Cancer Cell , 2005, 7(2): 143–153 doi: 10.1016/j.ccr.2005.01.005 pmid:15710327
29
Lallemand-Breitenbach V, Zhu J, Puvion F, Koken M, Honoré N, Doubeikovsky A, Duprez E, Pandolfi P P, Puvion E, Freemont P, de Thé H. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med , 2001, 193(12): 1361–1371 doi: 10.1084/jem.193.12.1361 pmid:11413191
30
Zhang X W, Yan X J, Zhou Z R, Yang F F, Wu Z Y, Sun H B, Liang W X, Song A X, Lallemand-Breitenbach V, Jeanne M, Zhang Q Y, Yang H Y, Huang Q H, Zhou G B, Tong J H, Zhang Y, Wu J H, Hu H Y, de Thé H, Chen S J, Chen Z. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science , 2010, 328(5975): 240–243 doi: 10.1126/science.1183424 pmid:20378816
31
Nasr R, Lallemand-Breitenbach V, Zhu J, Guillemin M C, de Thé H. Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure. Clin Cancer Res , 2009, 15(20): 6321–6326 doi: 10.1158/1078-0432.CCR-09-0209 pmid:19808868
32
Wang J C, Dick J E. Cancer stem cells: lessons from leukemia. Trends Cell Biol , 2005, 15(9): 494–501 doi: 10.1016/j.tcb.2005.07.004 pmid:16084092
33
Grignani F, Ferrucci P F, Testa U, Talamo G, Fagioli M, Alcalay M, Mencarelli A, Grignani F, Peschle C, Nicoletti I, .The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell , 1993, 74(3): 423–431 doi: 10.1016/0092-8674(93)80044-F pmid:8394219
34
Du C, Redner R L, Cooke M P, Lavau C. Overexpression of wild-type retinoic acid receptor alpha (RARalpha) recapitulates retinoic acid-sensitive transformation of primary myeloid progenitors by acute promyelocytic leukemia RARalpha-fusion genes. Blood , 1999, 94(2): 793–802 pmid:10397747
35
Nasr R, Guillemin M C, Ferhi O, Soilihi H, Peres L, Berthier C, Rousselot P, Robledo-Sarmiento M, Lallemand-Breitenbach V, Gourmel B, Vitoux D, Pandolfi P P, Rochette-Egly C, Zhu J, de Thé H. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med , 2008, 14(12): 1333–1342 doi: 10.1038/nm.1891 pmid:19029980
36
Delva L, Cornic M, Balitrand N, Guidez F, Micléa J M, Delmer A, Teillet F, Fenaux P, Castaigne S, Degos L, .Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells. Blood , 1993, 82(7): 2175–2181 pmid:8400267
37
Zheng X, Seshire A, Rüster B, Bug G, Beissert T, Puccetti E, Hoelzer D, Henschler R, Ruthardt M. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells. Haematologica , 2007, 92(3): 323–331 doi: 10.3324/haematol.10541 pmid:17339181
Ito K, Bernardi R, Morotti A, Matsuoka S, Saglio G, Ikeda Y, Rosenblatt J, Avigan D E, Teruya-Feldstein J, Pandolfi P P. PML targeting eradicates quiescent leukaemia-initiating cells. Nature , 2008, 453(7198): 1072–1078 doi: 10.1038/nature07016 pmid:18469801
40
Luesink M, Pennings J L, Wissink W M, Linssen P C, Muus P, Pfundt R, de Witte T J, van der Reijden B A, Jansen J H. Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome. Blood , 2009, 114(27): 5512–5521 doi: 10.1182/blood-2009-02-204834 pmid:19828696
41
Tallman M S, Andersen J W, Schiffer C A, Appelbaum F R, Feusner J H, Ogden A, Shepherd L, Rowe J M, Fran?ois C, Larson R S, Wiernik P H. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood , 2000, 95(1): 90–95 pmid:10607690
42
Ng J C, Wang J, Shraim A. A global health problem caused by arsenic from natural sources. Chemosphere , 2003, 52(9): 1353–1359 doi: 10.1016/S0045-6535(03)00470-3 pmid:12867164
43
Ficker E, Kuryshev Y A, Dennis A T, Obejero-Paz C, Wang L, Hawryluk P, Wible B A, Brown A M. Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol , 2004, 66(1): 33–44 doi: 10.1124/mol.66.1.33 pmid:15213294
44
Kojima C, Ramirez D C, Tokar E J, Himeno S, Drobná Z, Styblo M, Mason R P, Waalkes M P. Requirement of arsenic biomethylation for oxidative DNA damage. J Natl Cancer Inst , 2009, 101(24): 1670–1681 doi: 10.1093/jnci/djp414 pmid:19933942
45
Hughes M F. Arsenic methylation, oxidative stress and cancer—is there a link? J Natl Cancer Inst , 2009, 101(24): 1660–1661 doi: 10.1093/jnci/djp437 pmid:19933940
46
Lu D P, Qiu J Y, Jiang B, Wang Q, Liu K Y, Liu Y R, Chen S S. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood , 2002, 99(9): 3136–3143 doi: 10.1182/blood.V99.9.3136 pmid:11964275
47
The Cooperation Group of Phase II Clinical Trial of Compound Huangdai Tablet. Phase II clinical trial of compound Huangdai tablet in newly diagnosed acute promyelocytic leukemia. Chin J Hematol , 2006, 27(12): 801–804
48
Sun F, Chen N N, Cheng Y B. Compound realgar and natural indigo tablets in treatment of acute promyelocytic leukemia: a summary of experience in 204 cases. Zhong Xi Yi Jie He Xue Bao , 2008, 6(6): 639–642 doi: 10.3736/jcim20080618 pmid:18559245
49
Au W Y, Kumana C R, Kou M, Mak R, Chan G C, Lam C W, Kwong Y L. Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. Blood , 2003, 102(1): 407–408 doi: 10.1182/blood-2003-01-0298 pmid:12814916
50
Siu C W, Au W Y, Yung C, Kumana C R, Lau C P, Kwong Y L, Tse H F. Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety. Blood , 2006, 108(1): 103–106 doi: 10.1182/blood-2006-01-0054 pmid:16514059
